Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to an aging population, the launch of vaccination programs, increased awareness of respiratory illnesses, government health initiatives, and seasonal respiratory illness outbreaks.

Growth during the market's forecast period can be attributed to the expanding elderly population, increased vaccine access and global distribution, a greater emphasis on preventative healthcare, a rising incidence of respiratory infections, and improved healthcare policies and coverage. Key trends in the forecast period include advancements in vaccine technology, personalized medicine, integration of wearable health technology, innovations in vaccine delivery, cold chain logistics, and smart packaging.

The growing prevalence of respiratory syncytial virus (RSV) infections is expected to drive the growth of the abrysvo or arexvy market in the future. RSV infections are caused by the respiratory syncytial virus, a common virus that primarily affects the respiratory system, leading to mild cold-like symptoms in most individuals, but potentially severe illness in infants, older adults, and those with weakened immune systems. The increasing prevalence of RSV infections is fueled by the virus's highly contagious nature, seasonal outbreaks, lack of widespread immunity, and heightened vulnerability among populations such as infants and the elderly. Abrysvo helps address this issue by providing targeted vaccines to protect high-risk groups, such as older adults and infants, from severe RSV-related illnesses. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, reported that during the 2024-25 season, the hospitalization rate for RSV was 3.2 per 100,000 individuals. As a result, the rising prevalence of RSV infections is driving the growth of the abrysvo or arexvy market.

The increase in healthcare expenditure is also expected to support the growth of the abrysvo or arexvy market. Healthcare expenditure refers to the financial investment made by governments, private insurers, and individuals into the healthcare system to enhance and expand medical services. This rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, a higher demand for healthcare services, and rising costs of pharmaceuticals and treatments. Increased healthcare spending provides more financial resources for advanced treatment options, including biologic therapies, which benefits the Abrysvo or Arexvy market. For instance, in May 2023, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is contributing to the growth of the abrysvo or arexvy market.

A key trend in the abrysvo or arexvy market is the expansion of age indications to extend the vaccine’s use to a broader range of age groups, thereby enhancing public health protection and increasing market reach. The bivalent RSV prefusion F (RSVpreF) vaccine is designed to provide immunity against respiratory syncytial virus (RSV), targeting both the RSV-A and RSV-B subtypes. For example, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for ABRYSVO (RSV Vaccine), a bivalent RSVpreF vaccine, to prevent lower respiratory tract disease in adults aged 18 to 59 at increased risk, thus broadening its indication to a wider adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 months.

Major companies operating in the abrysvo or arexvy market are Pfizer Inc. and GlaxoSmithKline plc (GSK).

North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in abrysvo or arexvy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the abrysvo or arexvy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Abrysvo (also known as Arexvy) is a vaccine developed to prevent respiratory syncytial virus (RSV) in adults aged 60 and older. It is intended to lower the risk of severe illness caused by RSV, which can lead to respiratory complications in older adults.

The primary clinical indications for the abrysvo or arexvy vaccine are RSV prevention and infant protection. RSV prevention involves using medical treatments or vaccines to reduce the risk of infection by the respiratory syncytial virus, which can cause serious respiratory issues, particularly in infants, the elderly, and individuals with weakened immune systems. The vaccine targets various age groups, including adults (18-59 years), older adults (60+ years), and pregnant individuals (32-36 weeks of gestation), with several end users including healthcare providers, pregnant individuals, and high-risk adults.

The abrysvo or arexvy market research report is one of a series of new reports that provides abrysvo or arexvy market statistics, including abrysvo or arexvy industry global market size, regional shares, competitors with an abrysvo or arexvy market share, detailed abrysvo or arexvy market segments, market trends, and opportunities, and any further data you may need to thrive in the abrysvo or arexvy industry. This abrysvo or arexvy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The abrysvo or arexvy market consists of sales of prefilled syringes, vaccine vials, vaccine storage equipment, syringes, and needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.